Haemonetics Corp. 10-Q Summary: Quarter Ended July 1, 2000
Business Context and Reporting Period
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems, including blood bank, surgical, and plasma products. This report covers the three-month period ended July 1, 2000 (First Quarter of Fiscal Year 2001). The company operates globally, with over two-thirds of revenues generated outside the United States.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Net Revenues | $69.7 million | $69.1 million |
| Gross Profit | $33.4 million (47.9% margin) | $32.8 million (47.5% margin) |
| Operating Income | $8.3 million (11.9% margin) | $8.5 million (12.2% margin) |
| Net Income | $6.7 million | $6.0 million |
| Diluted EPS | $0.26 | $0.22 |
| Cash from Operations | $5.9 million | $11.3 million |
| Net Debt | $13.8 million | $12.9 million |
| Working Capital | $128.9 million | $121.4 million |
Material Changes vs. Prior Period
- Revenue: Net revenues increased 0.8% to $69.7 million. However, at constant currency rates, revenues decreased 0.4%. The increase was driven by a 59.4% rise in miscellaneous and service revenue, offset by a 32.6% decline in equipment sales due to a non-recurring international sale in the prior year.
- Profitability: Net income rose 11.6% to $6.7 million, primarily due to a lower effective tax rate (28.0% vs. 32.0%) and increased interest income. Operating income declined slightly ($0.1 million) due to higher Research and Development (R&D) expenses.
- Cash Flow: Operating cash flow decreased significantly by $5.4 million to $5.9 million. This was largely due to a $3.0 million change in accounts receivable and a $3.7 million increase in prepaid income taxes and other assets.
- Debt: Net debt increased by $0.9 million to $13.8 million. The company reduced its short-term revolving credit agreements by $8.1 million but repurchased $4.7 million of treasury stock.
Outlook, Risks, and Management Commentary
- Guidance: Management expects the effective tax rate to remain at 28% for the full fiscal year 2001. No specific revenue or earnings guidance was provided for the remainder of the year.
- Market Risks: The company faces significant foreign exchange risk, as over 68% of revenues are international. A 10% strengthening of the U.S. dollar would result in a $12.7 million unrealized gain on forward contracts, while a 10% weakening would result in a $14.8 million unrealized loss.
- Accounting Changes: The company is evaluating the impact of SAB No. 101 (Revenue Recognition) and SFAS No. 133 (Derivatives and Hedging), with adoption expected in fiscal year 2001 or 2002. The impact on financial statements has not yet been determined.
- Euro Conversion: The company is preparing for the Euro currency adoption in Europe, targeting an information system conversion by April 1, 2001. Management does not anticipate a material financial impact.
Investor Verification Checklist
- Verify the sustainability of the 59.4% increase in "Misc & service" revenue, which offset declines in equipment sales.
- Monitor the impact of the U.S. dollar strength on future reported revenues, given the 68% international exposure.
- Assess the trend in operating cash flow, which dropped 48% year-over-year despite higher net income.
- Review the company's progress on adopting SFAS No. 133 and SAB No. 101 for potential future accounting adjustments.
- Confirm the stability of the commercial plasma business, which faced a donor shortage contributing to a 2.0% revenue decline in that segment.